Regensburg, March 17, 2008 - The GENEART AG, global market leader for the production of synthetic genes and specialist in the field of synthetic biology, enters a contract worth EUR 0.3M for its contribution as a partner in the major EU project titled “New HIV Vaccines Inducing Broadly Reactive Neutralising Antibodies”.The project is coordinated by sanofi pasteur - the vaccines division of sanofi-aventis Group - and aims at the development of a broad spectrum vaccine against HIV. The consortium behind the project comprises 15 research groups and has received a total contribution of almost EUR 12M. GENEART develops and synthesizes the needed gene constructs for the efficient production of the vaccine candidates.
